Compare GLBS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBS | INTS |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 24.0M |
| IPO Year | 2007 | 2023 |
| Metric | GLBS | INTS |
|---|---|---|
| Price | $1.75 | $0.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $4.33 |
| AVG Volume (30 Days) | 278.3K | ★ 3.9M |
| Earning Date | 11-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,444,000.00 | N/A |
| Revenue This Year | $16.13 | N/A |
| Revenue Next Year | $20.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.49 | N/A |
| 52 Week Low | $0.99 | $0.19 |
| 52 Week High | $1.99 | $3.17 |
| Indicator | GLBS | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 68.40 | 56.47 |
| Support Level | $1.72 | $0.46 |
| Resistance Level | $1.99 | $0.54 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 70.24 | 84.23 |
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.